Descriptive Study of the Incidence of Malignancy in Severe Asthma Patients Receiving Benralizumab and Other Biologic Therapy, a Post Authorization Safety Study

NCT04991805 · clinicaltrials.gov ↗
COMPLETED
Status
14000
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

AstraZeneca